Rathbones Group Discloses Shareholding Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2026
0mins
Should l Buy AMS?
Source: Yahoo Finance
- Shareholding Disclosure: Rathbones Group disclosed its shareholding in Advanced Medical Solutions Group plc on April 22, 2026, holding 14,390,925 ordinary shares, representing 6.55% of the relevant securities, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: The latest disclosure includes multiple stock transactions, selling 1,770 shares, 3,856 shares, 2,710 shares, and 941 shares at prices of 260.692 pence, 258.661 pence, 257.50 pence, and 257.38 pence respectively, indicating active market participation.
- Compliance and Transparency: This disclosure aligns with the requirements of the Takeover Code, enhancing investor trust in Rathbones' compliance and transparency, which may positively impact its stock price stability.
- Market Reaction Expectations: Although this disclosure does not involve significant transactions or changes, the transparent shareholding information may influence market confidence in Rathbones, especially in the context of investor focus on corporate governance and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMS
About AMS
American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rathbones Group Discloses Shareholding Information
- Shareholding Disclosure: Rathbones Group disclosed its shareholding in Advanced Medical Solutions Group plc on April 22, 2026, holding 14,390,925 ordinary shares, representing 6.55% of the relevant securities, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: The latest disclosure includes multiple stock transactions, selling 1,770 shares, 3,856 shares, 2,710 shares, and 941 shares at prices of 260.692 pence, 258.661 pence, 257.50 pence, and 257.38 pence respectively, indicating active market participation.
- Compliance and Transparency: This disclosure aligns with the requirements of the Takeover Code, enhancing investor trust in Rathbones' compliance and transparency, which may positively impact its stock price stability.
- Market Reaction Expectations: Although this disclosure does not involve significant transactions or changes, the transparent shareholding information may influence market confidence in Rathbones, especially in the context of investor focus on corporate governance and compliance.
See More
AMS Reports Revenue Decline but Improved Losses in Q4 2025
- Revenue Decline: Total revenue for Q4 2025 was $7.7 million, a 14.8% decrease year-over-year, primarily due to the expiration of three Gamma Knife contracts and reduced proton radiation therapy volumes, highlighting the company's vulnerability in revenue diversification.
- Growth in Direct Patient Care Services: Revenue from direct patient care services reached $4.8 million, accounting for 63% of total revenue and reflecting a 2.6% year-over-year increase, indicating stability and long-term growth potential in this segment.
- Significant Gross Margin Decline: The gross margin for Q4 dropped to 12%, down from 35% in the previous year, illustrating the negative impact of reduced treatment volumes and a shift in revenue mix on profitability.
- Improved Net Loss: The net loss for Q4 was $631,000, an improvement from a net loss of $1.6 million in the same quarter last year, yet it still presents challenges for the company's recovery in profitability.
See More
American Shared Hospital Services Q4 2025 Earnings Call Insights
- Revenue Stability: Total revenue for 2025 was $28.1 million, with AMS transitioning towards a direct patient care model that now constitutes 63% of total revenue, indicating resilience and potential growth despite challenges like physician turnover and leasing segment headwinds.
- Partnership Updates: AMS has established a new collaboration with Brown University Health in Rhode Island and extended its long-standing relationship with Orlando Health by a 7-year lease, which not only strengthens the company's market position but also secures future revenue growth opportunities.
- Financial Warning: Q4 revenue decreased by 14.8% to $7.7 million, primarily due to the expiration of three Gamma Knife contracts and reduced proton beam therapy volumes, raising significant doubts about the company's ability to continue as a going concern, necessitating active negotiations with lenders to improve capital structure.
- Future Outlook: Management did not provide specific EPS or revenue guidance but emphasized priorities such as increasing treatment volumes and operational efficiencies, with Rhode Island expansion expected to come online in late 2027 and the proton facility in 2028, reflecting confidence in future growth.
See More
American Shared Hospital Q4 Earnings Report
- Disappointing Earnings: American Shared Hospital reported a Q4 GAAP EPS of -$0.09, indicating ongoing challenges in profitability and reflecting a deterioration in its financial health.
- Revenue Decline: The reported revenue of $7.73 million represents a 14.8% year-over-year decline, missing market expectations by $1.05 million, suggesting significant pressure on business growth.
- Negative Market Reaction: The failure to meet earnings expectations may negatively impact the stock price, exacerbating market concerns about the company's future performance and potentially leading to a decline in investor confidence.
- Uncertain Future Outlook: Given the current economic environment, the continued revenue decline and losses may force the company to reassess its strategic direction to address market challenges and restore profitability.
See More
ams OSRAM Sells Sensor Business to Infineon for €570 Million
- Transaction Overview: ams OSRAM has agreed to sell its non-optical analog/mixed-signal sensor business to Infineon for €570 million in cash, with the business generating approximately €220 million in annual revenue and €60 million in adjusted EBITDA in 2025, significantly improving the company's leverage ratio.
- Strategic Transformation: This sale allows ams OSRAM to focus on the Digital Photonics sector, reducing its leverage ratio to 2.5, thereby enhancing its competitiveness in rapidly growing markets such as automotive, augmented reality, and robotics, driving long-term growth.
- Investment Plans: ams OSRAM intends to intensify investments in high-pixel EVIYOS™ forward lighting solutions and optical interconnect technologies to meet global demand for Digital Photonics, which is expected to yield significant mid- to long-term growth opportunities for the company.
- Financial Targets: The company aims to achieve mid- to high single-digit revenue growth and an adjusted EBITDA margin of over 25% by 2030, with projected free cash flow exceeding €200 million, further solidifying its leadership position in the semiconductor market.
See More
UK Stock Market Declines, Hochschild Mining Undervalued by 48.9%
- Market Decline: The UK stock market, represented by the FTSE 100 and FTSE 250 indices, has recently faced declines due to weak trade data from China, highlighting the interconnectedness of global economies and prompting investors to navigate market uncertainties cautiously.
- Hochschild Mining Valuation: Trading at £5.73, Hochschild Mining is significantly undervalued compared to its estimated fair value of £11.22, indicating a 48.9% discount; despite recent declines in gold and silver production, the company forecasts a robust annual earnings growth of 40.8% over the next three years, surpassing UK market averages.
- Pan African Resources Outlook: Priced at £1.28, Pan African Resources is below its estimated fair value of £1.63, with expected annual earnings growth of 31.3% over the next three years, bolstered by its inclusion in multiple FTSE indices, enhancing production capabilities and operational efficiencies.
- Raspberry Pi Holdings Growth Potential: Raspberry Pi Holdings is trading at £2.9, below its estimated fair value of £3.28, with anticipated annual earnings growth of 46.2%; despite recent executive changes, the company is expected to achieve a 16.8% revenue increase, indicating strong financial performance potential.
See More
Rathbones Group Discloses Shareholding Information
- Shareholding Disclosure: Rathbones Group disclosed its shareholding in Advanced Medical Solutions Group plc on April 22, 2026, holding 14,390,925 ordinary shares, representing 6.55% of the relevant securities, complying with Rule 8.3 of the Takeover Code to ensure market transparency.
- Trading Activity Overview: The latest disclosure includes multiple stock transactions, selling 1,770 shares, 3,856 shares, 2,710 shares, and 941 shares at prices of 260.692 pence, 258.661 pence, 257.50 pence, and 257.38 pence respectively, indicating active market participation.
- Compliance and Transparency: This disclosure aligns with the requirements of the Takeover Code, enhancing investor trust in Rathbones' compliance and transparency, which may positively impact its stock price stability.
- Market Reaction Expectations: Although this disclosure does not involve significant transactions or changes, the transparent shareholding information may influence market confidence in Rathbones, especially in the context of investor focus on corporate governance and compliance.
See More
AMS Reports Revenue Decline but Improved Losses in Q4 2025
- Revenue Decline: Total revenue for Q4 2025 was $7.7 million, a 14.8% decrease year-over-year, primarily due to the expiration of three Gamma Knife contracts and reduced proton radiation therapy volumes, highlighting the company's vulnerability in revenue diversification.
- Growth in Direct Patient Care Services: Revenue from direct patient care services reached $4.8 million, accounting for 63% of total revenue and reflecting a 2.6% year-over-year increase, indicating stability and long-term growth potential in this segment.
- Significant Gross Margin Decline: The gross margin for Q4 dropped to 12%, down from 35% in the previous year, illustrating the negative impact of reduced treatment volumes and a shift in revenue mix on profitability.
- Improved Net Loss: The net loss for Q4 was $631,000, an improvement from a net loss of $1.6 million in the same quarter last year, yet it still presents challenges for the company's recovery in profitability.
See More
American Shared Hospital Services Q4 2025 Earnings Call Insights
- Revenue Stability: Total revenue for 2025 was $28.1 million, with AMS transitioning towards a direct patient care model that now constitutes 63% of total revenue, indicating resilience and potential growth despite challenges like physician turnover and leasing segment headwinds.
- Partnership Updates: AMS has established a new collaboration with Brown University Health in Rhode Island and extended its long-standing relationship with Orlando Health by a 7-year lease, which not only strengthens the company's market position but also secures future revenue growth opportunities.
- Financial Warning: Q4 revenue decreased by 14.8% to $7.7 million, primarily due to the expiration of three Gamma Knife contracts and reduced proton beam therapy volumes, raising significant doubts about the company's ability to continue as a going concern, necessitating active negotiations with lenders to improve capital structure.
- Future Outlook: Management did not provide specific EPS or revenue guidance but emphasized priorities such as increasing treatment volumes and operational efficiencies, with Rhode Island expansion expected to come online in late 2027 and the proton facility in 2028, reflecting confidence in future growth.
See More
American Shared Hospital Q4 Earnings Report
- Disappointing Earnings: American Shared Hospital reported a Q4 GAAP EPS of -$0.09, indicating ongoing challenges in profitability and reflecting a deterioration in its financial health.
- Revenue Decline: The reported revenue of $7.73 million represents a 14.8% year-over-year decline, missing market expectations by $1.05 million, suggesting significant pressure on business growth.
- Negative Market Reaction: The failure to meet earnings expectations may negatively impact the stock price, exacerbating market concerns about the company's future performance and potentially leading to a decline in investor confidence.
- Uncertain Future Outlook: Given the current economic environment, the continued revenue decline and losses may force the company to reassess its strategic direction to address market challenges and restore profitability.
See More
ams OSRAM Sells Sensor Business to Infineon for €570 Million
- Transaction Overview: ams OSRAM has agreed to sell its non-optical analog/mixed-signal sensor business to Infineon for €570 million in cash, with the business generating approximately €220 million in annual revenue and €60 million in adjusted EBITDA in 2025, significantly improving the company's leverage ratio.
- Strategic Transformation: This sale allows ams OSRAM to focus on the Digital Photonics sector, reducing its leverage ratio to 2.5, thereby enhancing its competitiveness in rapidly growing markets such as automotive, augmented reality, and robotics, driving long-term growth.
- Investment Plans: ams OSRAM intends to intensify investments in high-pixel EVIYOS™ forward lighting solutions and optical interconnect technologies to meet global demand for Digital Photonics, which is expected to yield significant mid- to long-term growth opportunities for the company.
- Financial Targets: The company aims to achieve mid- to high single-digit revenue growth and an adjusted EBITDA margin of over 25% by 2030, with projected free cash flow exceeding €200 million, further solidifying its leadership position in the semiconductor market.
See More
UK Stock Market Declines, Hochschild Mining Undervalued by 48.9%
- Market Decline: The UK stock market, represented by the FTSE 100 and FTSE 250 indices, has recently faced declines due to weak trade data from China, highlighting the interconnectedness of global economies and prompting investors to navigate market uncertainties cautiously.
- Hochschild Mining Valuation: Trading at £5.73, Hochschild Mining is significantly undervalued compared to its estimated fair value of £11.22, indicating a 48.9% discount; despite recent declines in gold and silver production, the company forecasts a robust annual earnings growth of 40.8% over the next three years, surpassing UK market averages.
- Pan African Resources Outlook: Priced at £1.28, Pan African Resources is below its estimated fair value of £1.63, with expected annual earnings growth of 31.3% over the next three years, bolstered by its inclusion in multiple FTSE indices, enhancing production capabilities and operational efficiencies.
- Raspberry Pi Holdings Growth Potential: Raspberry Pi Holdings is trading at £2.9, below its estimated fair value of £3.28, with anticipated annual earnings growth of 46.2%; despite recent executive changes, the company is expected to achieve a 16.8% revenue increase, indicating strong financial performance potential.
See More
